Valuation : NovoCure Limited

Market Cap 2.08B 1.79B 1.68B 1.53B 2.88B 197B 2.9B 19.88B 7.73B 100B 7.79B 7.62B 332B P/E 2026 *
-14.2x
P/E 2027 * -21.8x
Enterprise Value 1.97B 1.7B 1.59B 1.45B 2.73B 187B 2.75B 18.87B 7.34B 95.03B 7.4B 7.23B 315B EV / Sales 2026 *
2.71x
EV / Sales 2027 * 2.32x
Free-Float
90.04%
Yield 2026 *
-
Yield 2027 * -
1 day-0.51%
1 week+5.67%
Current month+19.34%
1 month+19.34%
3 months+6.94%
6 months+33.16%
Current year+36.97%
1 week 16.92
Extreme 16.92
18.21
1 month 15
Extreme 15
18.61
Current year 9.82
Extreme 9.82
21.45
1 year 9.82
Extreme 9.82
21.45
3 years 9.82
Extreme 9.82
34.13
5 years 9.82
Extreme 9.82
143.69
10 years 5.95
Extreme 5.95
232.76
Manager TitleAgeSince
Chief Executive Officer 46 30/11/2025
Director of Finance/CFO 52 31/12/2024
Chief Tech/Sci/R&D Officer - 16/01/2023
Director TitleAgeSince
Director/Board Member 59 31/12/2011
Chairman 63 31/12/2008
Director/Board Member 64 04/08/2011
Date Insider Type Main position Quantity % Market Cap. Importance
30/06/26 Free

Chief Executive Officer

1,905 0.0016%
30/06/26 Free

Head of Human Resources

1,905 0.0016%
30/06/26 Free

General Counsel

1,299 0.0011%
Change 5-day change 1-year change 3-year change Capi.($)
-0.42%+5.67%+45.28%-19.72% 2.08B
+0.42%-0.19%+19.91%+22.17% 12.67B
-1.41%-0.45%+16.36%+28.13% 7.03B
-1.05%-6.75%+48.66%+28.56% 6.32B
-0.87%-0.25% - - 5.64B
-1.20%-6.96%-13.79%+45.61% 5.14B
-1.18%+2.00%-30.61%-23.99% 3.89B
+0.33%+11.07%-3.06%+132.43% 1.77B
-1.57%+3.14%+48.24%-13.31% 1.62B
-1.47%+1.97%-5.05%+17.40% 1.36B
Average -0.75%+0.63%+13.99%+24.14% 4.75B
Weighted average by Cap. -0.64%-0.89%+15.40%+23.78%

Financials

2026 *2027 *
Net sales 726M 625M 587M 536M 1.01B 69.06B 1.01B 6.95B 2.71B 35.02B 2.73B 2.67B 116B 805M 693M 651M 594M 1.12B 76.57B 1.12B 7.71B 3B 38.83B 3.02B 2.96B 129B
Net income -142M -122M -115M -105M -197M -13.51B -198M -1.36B -529M -6.85B -533M -522M -22.69B -84.78M -73M -68.54M -62.57M -118M -8.07B -118M -812M -316M -4.09B -318M -311M -13.54B
Net Debt -105M -90.82M -85.27M -77.84M -146M -10.04B -147M -1.01B -393M -5.09B -396M -387M -16.85B -210M -181M -170M -155M -291M -19.97B -293M -2.01B -782M -10.13B -788M -771M -33.54B
Logo NovoCure Limited
NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
Employees
1,605
Date Price Change Volume
31/08/26 US$17.70 -0.67% 266,073
28/08/26 US$17.82 -0.94% 855,579
27/08/26 US$17.99 +0.56% 763,436
26/08/26 US$17.89 +1.53% 1,270,871
25/08/26 US$17.62 +5.13% 902,955
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
17.82USD
Average target price
27.14USD
Spread / Average Target
+52.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NVCR Stock